New York University

The Scripps Research Institute

University of Southern California

Cell Matrix, Inc.

Maine Medical Center

Maine Medical Center Research Institute

Mainehealth

Peter C Brooks

David A Cheresh

Dorothy Rodriguez

Jeffry Dean Watkins

William D Huse

Ying Tang

Daniel Broek

Jennifer M Caron

Danielle Morais

Jingsong Xu

Leonard Liebes

Eric Petitclerc

Liangru Contois

Jennifer Roth

Abebe Akalu

Martin Friedlander

James Wayne Canary

Leif Oxburgh

Elissa Kramer

Bruce Ng

Steven A Silletti

The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.

Enhancing the therapeutic activity of an immune checkpoint inhibitor

Enhancing the therapeutic activity of immune checkpoint inhibitor

The present invention features compositions featuring agents that bind to denatured collagen and methods of using such agents to treat or prevent fibrosis or inflammation in a subject.

Compositions and methods for treating inflammation and fibrosis

The present invention provides a method of treating cancer using benzoic acid derivatives, alone or in combination with standard treatments such as chemotherapy and radiotherapy. Also provided are methods of screening for benzoic derivatives based on their ability to inhibit the enzyme tyrosinase or to bind to and activate PXR/SXR xenobiotic receptors.

Treatment of cancer using benzoic acid derivatives

The present invention provides a method of treating cancer using the sodium salt of a benzoic acid derivative, alone or in combination with standard treatments such as chemotherapy and radiotherapy.

Treatment of cancer using the sodium salt of a benzoic acid derivative

The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.

CLK-peptide and SLK-peptide

The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations thereof. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis is normal or diseased tissues both in vivo and ex vivo. Antagonists include monoclonal antibodies referred to as HUI77, HUIV26, and XL313.

Antagonists and methods for inhibiting angiogenesis

The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.

Humanized collagen antibodies and related methods

The present invention relates to a method for treating non-melanotic cancers by administration of PABA. The present invention also relates to the potentiation of standard cancer treatment of radiation, radioimmunotherapy, and/or chemotherapy using PABA.

Methods for treating non-melanoma cancers with PABA

The present invention relates to the inhibition of melanogenesis with para-aminobenzoic acid (PABA) and its use in treating melanotic cancer.

Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)

The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo.

Growing community of inventors

Carmel, NY, United States of America

Peter C Brooks